title: Personalized treatment of lung cancer.
abstract: Lung cancer is a heterogenous group of disorders, and a difficult disease to treat. The traditional approach of surgical resection for early-stage disease, potentially followed by chemotherapy, as well chemotherapy (with or without radiation) in later stages of disease is being supplemented with a personalized approach. The personalized approach has classically been used by the oncologist based on clinical/pathological parameters such as the performance status of the patient and histology of lung cancer. As molecular mechanisms have been explored in lung cancer more recently, the personalized approach also has incorporated molecular abnormalities. In particular, EGFR, K-ras, ALK, MET, CBL, and COX2, have come to the forefront as potential biomarkers and therapeutic targets. Thus, we review the various molecular mechanisms in lung cancer and the role of novel therapeutics.
authors.affiliation: Department of Medicine, The University of Chicago, Chicago, IL 60637, USA. rsalgia@medicine.bsd.uchiago.edu
authors.forename: Ravi
authors.initials: R
authors.lastname: Salgia
authors.forename: Thomas
authors.initials: T
authors.lastname: Hensing
authors.forename: Nicholas
authors.initials: N
authors.lastname: Campbell
authors.forename: April K
authors.initials: AK
authors.lastname: Salama
authors.forename: Michael
authors.initials: M
authors.lastname: Maitland
authors.forename: Philip
authors.initials: P
authors.lastname: Hoffman
authors.forename: Victoria
authors.initials: V
authors.lastname: Villaflor
authors.forename: Everett E
authors.initials: EE
authors.lastname: Vokes
mesh_terms: D019008:Drug Resistance, Neoplasm; D066246:ErbB Receptors / Q000037:antagonists & inhibitors / Q000235:genetics; D011905:Genes, ras; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D009154:Mutation; D009360:Neoplastic Cells, Circulating; D015514:Oncogene Proteins, Fusion / Q000037:antagonists & inhibitors / Q000235:genetics; D057285:Precision Medicine; D011379:Prognosis; D019859:Proto-Oncogene Proteins c-met / Q000037:antagonists & inhibitors / Q000235:genetics; D017978:Receptors, Growth Factor / Q000037:antagonists & inhibitors / Q000235:genetics
chemical_list: C522504:EML4-ALK fusion protein, human; D015514:Oncogene Proteins, Fusion; D017978:Receptors, Growth Factor; D066246:ErbB Receptors; C491743:MET protein, human; D019859:Proto-Oncogene Proteins c-met